MCID: HDG012
MIFTS: 73

Hodgkin Lymphoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hodgkin Lymphoma

MalaCards integrated aliases for Hodgkin Lymphoma:

Name: Hodgkin Lymphoma 54 12 50 24 29 13 38
Hodgkin Disease 12 50 71 52 41 69
Hodgkin's Lymphoma 38 12 50 14
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 69
Hodgkin's Disease of Intrapelvic Lymph Nodes 69
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Classic 71
Classic Hodgkin Lymphoma 56
Classic Hodgkin Disease 56
Lymphoma, Hodgkin's 50
Hodgkin's Sarcoma 12
Hodgkins Lymphoma 12
Chl 71
Hl 12

Characteristics:

Orphanet epidemiological data:

56
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

54
Inheritance:
autosomal recessive


HPO:

32
hodgkin lymphoma:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Hodgkin Lymphoma

NIH Rare Diseases : 50 the following summary is from orphanet, a european reference portal for information on rare diseases and orphan drugs.orpha number: 98293disease definitionhodgkin lymphoma (hl) is a heterogeneous group of malignant lymphoid neoplasms of b-cell origin characterized histologically by the presence of hodgkin and reed-sternberg (hrs) cells in the vast majority of cases.epidemiologyhl is an uncommon cancer with an incidence of about 1/40,000 in north america and europe. there are about 8500 new cases reported in the u.s. each year.clinical descriptionhl is comprised of 2 major forms: classical hodgkin lymphoma (chl; see this term), seen in 95% of all hl cases, and nodular lymphocyte predominant hodgkin lymphoma (nlphl; see this term), seen in only 5% of all hl cases. disease onset occurs most frequently in young adults (age 15-35) followed by older adults (over the age of 55) and usually begins with the painless swelling of a lymph node in the upper body. disease can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients.etiologythe exact cause is unknown but immunological, genetic and environmental factors are thought to be involved.management and treatmenttreatment with radiotherapy and systemic chemotherapy leads to a very good prognosis. follow-up physical exams, blood tests and x-rays are needed to check for recurrence and check for any long-term side effects of the toxic treatments. possible long-term side effects include secondary cancers, infertility, reduced immunity, thyroid problems, heart disease and stroke.prognosisthe international prognostic score (ips) is a score given based on the presence of 7 risk factors (male sex, >45 years of age, stage 4 disease, serum albumin 15,000/mm3) at the time of diagnosis. the more factors present, the less favorable the prognosis. the cure rates are 90% for early-stage hl and 70% for advance stage hl.visit the orphanet disease page for more resources. last updated: 10/1/2012

MalaCards based summary : Hodgkin Lymphoma, also known as hodgkin disease, is related to hodgkin's lymphoma, lymphocytic-histiocytic predominance and hemolytic anemia, and has symptoms including ataxia, headache and hepatomegaly. An important gene associated with Hodgkin Lymphoma is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are hematopoietic system and immune system

UniProtKB/Swiss-Prot : 71 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

MedlinePlus : 41 hodgkin disease is a type of lymphoma. lymphoma is a cancer of a part of the immune system called the lymph system. the first sign of hodgkin disease is often an enlarged lymph node. the disease can spread to nearby lymph nodes. later it may spread to the lungs, liver, or bone marrow. the exact cause is unknown. hodgkin disease is rare. symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin fever and chills night sweats weight loss loss of appetite itchy skin to diagnose hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. treatment depends on how far the disease has spread. it often includes radiation therapy or chemotherapy. the earlier the disease is diagnosed, the more effective the treatment. in most cases, hodgkin disease can be cured. nih: national cancer institute

OMIM : 54
Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000)

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

Wikipedia : 72 Hodgkin\'s lymphoma (HL) is a type of lymphoma, which is generally believed to result from white blood... more...

Related Diseases for Hodgkin Lymphoma

Diseases related to Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
id Related Disease Score Top Affiliating Genes
1 hodgkin's lymphoma, lymphocytic-histiocytic predominance 32.6 ALK BCL6 NPM1 PAX5 TNFRSF8
2 hemolytic anemia 30.4 ALK CSF3 NPM1 PAX5 TNFRSF8
3 hepatoblastoma 29.8 BCL6 PAX5 REL TNFRSF8
4 lymphoma, non-hodgkin 12.2
5 nodular lymphocyte predominant hodgkin lymphoma 12.2
6 classic hodgkin lymphoma, mixed cellularity type 12.0
7 classic hodgkin lymphoma, lymphocyte-rich type 12.0
8 non-hodgkin lymphoma, during pregnancy 12.0
9 hodgkin lymphoma, during pregnancy 12.0
10 lymphoma 12.0
11 non-hodgkin lymphoma, childhood 11.9
12 hodgkin lymphoma, childhood 11.9
13 hodgkin's lymphoma, nodular sclerosis 11.5
14 hodgkin's lymphoma, lymphocytic depletion 11.5
15 b-cell lymphomas 11.5
16 anaplastic large cell lymphoma 11.4
17 gray zone lymphoma 11.4
18 hepatic lipase deficiency 11.3
19 diffuse large b-cell lymphoma 11.3
20 hodgkin's lymphoma, mixed cellularity 11.3
21 follicular lymphoma 11.3
22 progressive transformation of germinal centers 11.3
23 lymphoplasmacytic lymphoma 11.2
24 paraneoplastic cerebellar degeneration 11.2
25 composite lymphoma 11.2
26 primary central nervous system lymphoma 11.2
27 plasmablastic lymphoma 11.2
28 lymphoma, malt, somatic 11.2
29 familial hodgkin disease 11.1
30 thrombocytopenia, anemia, and myelofibrosis 11.0 BCL2 BCL6
31 pseudotyphus of california 10.9 BCL2 BCL6
32 idiopathic cd4-positive t-lymphocytopenia 10.9
33 orbital lymphoma 10.9
34 granulomatous slack skin disease 10.9
35 follicular lymphoma 1 10.9
36 primary oculocerebral lymphoma 10.9
37 cervical endometrioid adenocarcinoma 10.9 ALK BCL6
38 estrogen-receptor positive breast cancer 10.8 ALK BCL6 NPM1
39 allergic encephalomyelitis 10.8 ALK FSCN1
40 blake pouch cyst 10.8 BCL2 BCL6
41 urinary bladder small cell neuroendocrine carcinoma 10.8 BRAF CSF3
42 polycystic ovary syndrome 10.8 ALK BCL6 MS4A1
43 non-distal trisomy 10q 10.8 ALK BCL2 BRAF
44 mixed extragonadal germ cell cancer 10.8 ALK BCL2 NPM1
45 lipase deficiency, combined 10.8
46 hmg-coa lyase deficiency 10.8
47 hydrolethalus syndrome 10.8
48 penile disease 10.7 ALK BCL6 TNFRSF8
49 piussan lenaerts mathieu syndrome 10.7 MS4A1 TNFRSF8
50 congenital sucrase-isomaltase deficiency with starch intolerance 10.7 ALK NPM1

Graphical network of the top 20 diseases related to Hodgkin Lymphoma:



Diseases related to Hodgkin Lymphoma

Symptoms & Phenotypes for Hodgkin Lymphoma

Symptoms via clinical synopsis from OMIM:

54

Heme:
hodgkin disease

Lab:
impaired lymphocyte transformation with phytohemagglutinin
polyclonal elevation of igm


Clinical features from OMIM:

236000

Human phenotypes related to Hodgkin Lymphoma:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 ataxia 32 occasional (7.5%) HP:0001251
2 headache 32 occasional (7.5%) HP:0002315
3 hepatomegaly 32 occasional (7.5%) HP:0002240
4 splenomegaly 32 occasional (7.5%) HP:0001744
5 peripheral neuropathy 32 occasional (7.5%) HP:0009830
6 fatigue 32 hallmark (90%) HP:0012378
7 immunodeficiency 32 hallmark (90%) HP:0002721
8 dyspnea 32 occasional (7.5%) HP:0002094
9 bone pain 32 occasional (7.5%) HP:0002653
10 fever 32 frequent (33%) HP:0001945
11 cough 32 frequent (33%) HP:0012735
12 lymphadenopathy 32 hallmark (90%) HP:0002716
13 lymphoma 32 hallmark (90%) HP:0002665
14 weight loss 32 frequent (33%) HP:0001824
15 hyperhidrosis 32 frequent (33%) HP:0000975
16 pruritus 32 frequent (33%) HP:0000989
17 hemoptysis 32 occasional (7.5%) HP:0002105
18 impaired lymphocyte transformation with phytohemagglutinin 32 HP:0003347
19 polyclonal elevation of igm 32 HP:0003459
20 chest pain 32 frequent (33%) HP:0100749
21 anorexia 32 frequent (33%) HP:0002039
22 hodgkin lymphoma 32 HP:0012189

MGI Mouse Phenotypes related to Hodgkin Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 NPM1 PAX5 PRDM1 REL RHOH TNFRSF8
2 immune system MP:0005387 10.03 BCL2 BCL6 BRAF CSF3 FSCN1 LTA
3 mortality/aging MP:0010768 9.73 ALK BCL2 BCL6 BCL7A BRAF FSCN1
4 neoplasm MP:0002006 9.1 ALK BCL2 BRAF NPM1 PAX5 PRDM1

Drugs & Therapeutics for Hodgkin Lymphoma

FDA approved drugs:

(show all 10)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
3
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
4
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
5
Mozobil 17 46 PLERIXAFOR Genzyme December 2008
6
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech November 1997
7
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006
8
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
9
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
10
Zydelig 17 46 IDELALISIB Gilead July 2014

Drugs for Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 559)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
4 Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
10
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
11
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
12
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
13
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
14
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antilymphocyte Serum Phase 4,Phase 1,Phase 2
21 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
30 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
35 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
36 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
39 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
40 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
41 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
44 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
45 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
47
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
48
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
50
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 1196)

id Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
5 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
6 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
7 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
8 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
9 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma Unknown status NCT00678327 Phase 3 cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
10 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
11 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Unknown status NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
12 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
13 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
15 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
16 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
17 Exercise During Chemotherapy for Patients With Hematological Malignancies Unknown status NCT00884364 Phase 3
18 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
19 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
20 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) Completed NCT01034163 Phase 3 Panobinostat;Placebo
21 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
22 Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
23 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
24 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
25 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
26 Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
27 SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
28 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
29 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
30 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
31 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
32 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
33 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
34 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
35 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
36 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Completed NCT00039910 Phase 3 (PN-152,243)/ PN-196,444
37 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
38 A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). Completed NCT00838357 Phase 3 Generic = Plerixafor
39 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
40 Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
41 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
42 A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy Completed NCT00261677 Phase 3 epoetin alfa
43 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
44 Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy Completed NCT00041665 Phase 3 Recombinant Human Keratinocyte Growth Factor
45 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
46 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
47 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
48 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
49 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
50 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3

Search NIH Clinical Center for Hodgkin Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hodgkin Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Hodgkin Lymphoma

Genetic tests related to Hodgkin Lymphoma:

id Genetic test Affiliating Genes
1 Hodgkin Lymphoma 29 24 KLHDC8B

Anatomical Context for Hodgkin Lymphoma

MalaCards organs/tissues related to Hodgkin Lymphoma:

39
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Testes, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hodgkin Lymphoma:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Hodgkin Lymphoma

Articles related to Hodgkin Lymphoma:

(show top 50) (show all 1799)
id Title Authors Year
1
Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma. ( 28497317 )
2017
2
Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. ( 28911093 )
2017
3
Targeting non-Hodgkin Lymphoma with Blinatumomab. ( 28532177 )
2017
4
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. ( 28068241 )
2017
5
Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. ( 28942016 )
2017
6
PI3KI'-selective and PI3KI+/I'-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. ( 28945111 )
2017
7
Acquired TEF in Hodgkin Lymphoma in a Child: A Rare Clinical Association. ( 28060119 )
2017
8
Characterization of Alstrom Syndrome 1 (ALMS1) Transcript Variants in Hodgkin Lymphoma Cells. ( 28135309 )
2017
9
Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another. ( 28197347 )
2017
10
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. ( 28512788 )
2017
11
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28737231 )
2017
12
Associations between genetic variants in immunoregulatory genes and risk of non-Hodgkin lymphoma in a Chinese population. ( 28060727 )
2017
13
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL). ( 28952223 )
2017
14
Employment status and health related quality of life among Hodgkin-lymphoma survivors'- results based on data from a major treatment center in Hungary. ( 28927453 )
2017
15
Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. ( 27861844 )
2017
16
Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. ( 28737250 )
2017
17
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. ( 28802087 )
2017
18
Late onset progressive multifocal leukoencephalopathy in Hodgkin lymphoma. ( 28526178 )
2017
19
Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. ( 28498337 )
2017
20
Pure sensory ganglionopathy as the first sign of relapse in non-Hodgkin lymphoma. ( 28507261 )
2017
21
No association between radiation dose from pediatric CT scans and risk of subsequent Hodgkin lymphoma. ( 28052939 )
2017
22
Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation? ( 28369705 )
2017
23
Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma. ( 28515253 )
2017
24
Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 28522441 )
2017
25
Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. ( 28362442 )
2017
26
Primary classical Hodgkin lymphoma of rectum: Report of an extremely rare case and review of the literature. ( 28937385 )
2017
27
Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case-control study. ( 28503716 )
2017
28
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. ( 28851661 )
2017
29
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
30
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. ( 28040700 )
2017
31
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. ( 28042455 )
2017
32
Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. ( 28915338 )
2017
33
Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other. ( 28505189 )
2017
34
Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination. ( 28729340 )
2017
35
The role of FDG-PET in Hodgkin lymphoma. ( 28947879 )
2017
36
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups. ( 28220934 )
2017
37
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. ( 28902083 )
2017
38
Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015. ( 28935378 )
2017
39
Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. ( 28504035 )
2017
40
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. ( 28233899 )
2017
41
CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells. ( 27870927 )
2017
42
Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. ( 28914567 )
2017
43
Classic Hodgkin lymphoma in pelvis: A case report highlights diagnosis and treatment challenges. ( 28953683 )
2017
44
Novel Mutations in SH2D1A Gene in X-linked Lymphoproliferative Syndrome, Diagnosed After B-Cell Non-Hodgkin Lymphoma. ( 28267077 )
2017
45
Synchronous Presentation of Renal Cell Carcinoma and Hodgkin Lymphoma in an Adolescent. ( 28092312 )
2017
46
The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin lymphoma patients - the Polish Lymphoma Research Group (PLRG) Observational Study. ( 28950332 )
2017
47
T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28183747 )
2017
48
Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. ( 28061782 )
2017
49
Correlation of Patterns of Bone Marrow Infiltration and Biochemical factors in Non-Hodgkin Lymphoma. ( 28523057 )
2017
50
Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma. ( 28493609 )
2017

Variations for Hodgkin Lymphoma

ClinVar genetic disease variations for Hodgkin Lymphoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh37 Chromosome 3, 49209095: 49209095

Cosmic variations for Hodgkin Lymphoma:

9 (show all 21)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17
2 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17
3 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 17
4 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 17
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 17
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 17
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 17
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 17
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 17
10 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 17
11 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 17
12 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 17
13 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 17
14 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 17
15 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 17
16 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 17
17 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 17
18 COSM5761 CTNNB1 skin,neck,malignant melanoma,nodular c.131C>T p.P44L 4
19 COSM584 NRAS skin,upper arm,malignant melanoma,nodular c.182A>G p.Q61R 2
20 COSM580 NRAS skin,upper arm,malignant melanoma,nodular c.181C>A p.Q61K 2
21 COSM476 BRAF skin,upper arm,malignant melanoma,nodular c.1799T>A p.V600E 2

Copy number variations for Hodgkin Lymphoma from CNVD:

7 (show top 50) (show all 204)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma

Expression for Hodgkin Lymphoma

Search GEO for disease gene expression data for Hodgkin Lymphoma.

Pathways for Hodgkin Lymphoma

Pathways related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 ALK BCL2 BRAF CASP10 CSF3 LTA
2
Show member pathways
13.18 ALK BCL2 CSF3 LTA RHOH TNFRSF8
3
Show member pathways
13.04 BCL2 CASP10 CSF3 LTA RHOH TNFRSF8
4
Show member pathways
13.03 BCL2 BCL6 BRAF CSF3 FSCN1 LTA
5
Show member pathways
12.33 BCL2 CASP10 LTA TNFRSF8 TNFSF8
6 12.32 BCL6 PAX5 PRDM1 REL
7
Show member pathways
12.28 BRAF CASP10 REL RHOH
8 11.74 BCL2 BCL6 FSCN1
9 11.68 BCL2 BCL6 CASP10 PRDM1
10
Show member pathways
11.56 LTA TNFRSF8 TNFSF8
11
Show member pathways
11.32 BCL2 REL TNFRSF8 TNFSF8
12 11.1 BCL6 LTA PAX5 PRDM1
13 10.9 BCL2 CSF3 LTA TNFSF8
14 10.75 BCL6 MS4A1 PAX5 PRDM1 TNFRSF8

GO Terms for Hodgkin Lymphoma

Biological processes related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 CSF3 LTA LY75 TNFRSF8 TNFSF8
2 regulation of apoptotic process GO:0042981 9.62 ALK BCL2 BCL6 CASP10
3 animal organ morphogenesis GO:0009887 9.54 BCL2 BRAF PAX5
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.33 BCL2 BRAF CSF3
5 regulation of cell proliferation GO:0042127 9.26 ALK BCL6 BRAF PRDM1
6 humoral immune response GO:0006959 8.92 BCL2 LTA MS4A1 PAX5

Sources for Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....